Skip to main content

Remote Job Finders (RJF)

Argenx shutters Sjogren’s study, losing blockbuster expansion opportunity for Vyvgart

Argenx shares have fallen more than 13% after the surprise futility finding, which overshadowed a mid-stage celiac disease win for a separate asset acquired in the company’s $2.2 billion Forte Biosciences buy.

Beyond equity: Why venture debt is reshaping European biotech

In this episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba and Joey Mason, venture partner at Claret Capital. We dig into how venture debt buys time when equity can’t and how Europe’s funding gaps, tranching habits and slower urgency shape who uses it well.
Scroll to top